A trial study: the effect of low dose human chorionic gonadotropin on the symptoms of benign prostatic hyperplasia

What Was Tested

Researchers studied hCG (human chorionic gonadotropin) in the context of hyperparathyroidism in this randomized controlled trial publication.

Human chorionic gonadotropin (HCG) is a glycoprotein hormone with multiple physiological functions.

It interferes with mammary tumorigenesis and modulates growth and tumorigenesis in prostate cancer cells.

Functionally HCG has a growth modulating effect on androgen independent prostate cell lines.

Who Took Part

According to the abstract, 101 men were involved.

PubMed indexes the participants as middle-aged adults and older adults, men only.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, multicenter and pilot.

Because people in this hCG (human chorionic gonadotropin) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind hCG (human chorionic gonadotropin) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the hCG (human chorionic gonadotropin) group a baseline to be compared against.

More than one site took part, so the men came from several places.

What Was Measured

Topics PubMed links to this paper include Chorionic Gonadotropin, Pilot Projects and Prostatic Hyperplasia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of hCG (human chorionic gonadotropin) in 101 men in people with hyperparathyroidism.

Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (The Journal of urology), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page, Hyperparathyroidism research.